Big Pharma Getting Billions More Than Reported Out Of Senate Finance Bill

The introduction of the Senate Finance Committee's health care proposal turns the focus from what the pharmaceutical industry will contribute to reform efforts toward what manufacturers stand to gain.
The pharmaceutical industry could see an increase of approximately $115 billion over 10 years in U.S. drug sales as a direct result of the Senate Finance Committee's health reform legislation - at least by one way of slicing up the numbers used in economic analyses underlying the bill.
Read the whole story: The RPM Report